Macrophages Are Not Welcome: Potential of CCR1/CCR2 Inhibition for Cytokine Release Prevention.

Authors

Sebastian Kobold

Published in

Cancer immunology research. Pages OF1-OF2. Oct 30, 2026. Epub Oct 30, 2026.

Abstract

Chimeric antigen receptor (CAR) T cells can provide cures to patients affected by certain hematologic malignancies. Cytokine release syndrome (CRS) is a major side effect of this treatment, yet its pathophysiology remains incompletely understood and selective therapeutic options are limited. In this issue, Li and colleagues identify the CCR1-CCR2 axis as a key mediator of inflammatory macrophage recruitment to sites of CAR T-cell activation, thereby contributing to CRS. In preclinical models, blockade of this axis prevented macrophage recruitment and substantially diminished CRS severity. This discovery could open a new avenue for targeted intervention against CRS, although further validation of the role of the CCR1/CCR2 axis, particularly in clinically relevant settings, is required. See related article by Li and colleagues et al., p. XX.

PMID:
42961088
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.